Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB091 in Healthy Adult Participants
NCT03943056Phase 1Completed
- Sponsor
- Biogen
- Start
- May 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of biib091 in multiple sclerosis (MS) (8 cohorts), sponsored by Biogen. Primary endpoint: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs). Started May 2019; status: completed.
02
Drugs
biib091
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03943056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03943056.